De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Daan Gene Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Daan Gene heeft een totaal eigen vermogen van CN¥8.7B en een totale schuld van CN¥111.7M, wat de schuld-eigenvermogensverhouding op 1.3% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥10.1B en CN¥1.4B.

Belangrijke informatie

1.3%

Verhouding schuld/eigen vermogen

CN¥111.70m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥2.64b
Aandelen	CN¥8.72b
Totaal verplichtingen	CN¥1.41b
Totaal activa	CN¥10.13b

Recente financiële gezondheidsupdates

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

May 02

Recent updates

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Aug 20

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

May 02

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 05

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Mar 25

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Mar 06

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥5.2B ) 002030 } overtreffen de korte termijn passiva ( CN¥1.3B ).

Langlopende schulden: De kortetermijnactiva 002030 ( CN¥5.2B ) overtreffen de langetermijnschulden ( CN¥143.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 002030 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 002030 is de afgelopen 5 jaar gedaald van 37.6% naar 1.3%.

Schuldendekking: De schuld van 002030 wordt goed gedekt door de operationele kasstroom ( 750.7% ).

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 002030 op haar schulden goed worden gedekt door EBIT.

Daan Gene Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

Recent updates

Daan Gene Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.27 profit in 2Q 2023)

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

Daan Gene Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend reduced to CN¥0.015

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

First quarter 2024 earnings released: CN¥0.26 loss per share (vs CN¥0.026 profit in 1Q 2023)

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.075 (vs CN¥3.86 in FY 2022)

Daan Gene Co., Ltd., Annual General Meeting, Apr 19, 2024

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

Now 20% overvalued

Daan Gene Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: CN¥0.035 loss per share (vs CN¥0.94 profit in 3Q 2022)

Daan Gene Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥1.36 in 2Q 2022)

Less than half of directors are independent

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 13, 2023

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: CN¥3.95 (vs CN¥2.58 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.66 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.36 (vs CN¥0.33 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.34 (vs CN¥0.33 in 2Q 2021)

Insufficient new directors

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥1.11 per share

Daan Gene Co., Ltd. Proposes Final Cash Dividend on A Shares for the Year 2021, Payable on May 9, 2022

Insufficient new directors

Daan Gene Co., Ltd. Approves Final Dividend for the Year 2021

Daan Gene Co., Ltd., Annual General Meeting, Apr 20, 2022

Daan Gene Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Da An Gene Co., Ltd. of Sun Yat-Sen University Announces Final Dividend Implementation Plan (A Shares) for 2020, Payable on 19 May 2021

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.77 (vs CN¥0.10 in FY 2019)

New 90-day low: CN¥29.03

Da an Gene Co., Ltd. of Sun Yat-Sen University Announces Executive Changes

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report Fiscal Year 2020 Results on Mar 31, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.15

New 90-day low: CN¥31.98

Third quarter 2020 earnings released: EPS CN¥0.86

First half earnings released

First half earnings released

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥40.83

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven